Avammune Therapeutics Competitors and Similar CompaniesClear all
Avammune Therapeutics's competitors and similar companies include ImmuneSensor Therapeutics, FORMA Therapeutics, Halozyme Therapeutics and Pharmacyclics.
 Avammune Therapeutics Avammune Therapeutics (formerly Straximm Therapeutics) is a drug discovery company focused on cancer immunotherapy. |  ImmuneSensor Therapeutics ImmuneSensor Therapeutics is a company aiming to treat cancer and autoimmune diseases. |  FORMA Therapeutics FORMA Therapeutics is a biopharmaceutical company intended for the discovery, development, and commercialization of transformative medicines. |  Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. |  Pharmacyclics Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. | |
Founding Date | Founding Date 2018 | Founding Date 2014 | Founding Date 2008 | Founding Date 1998 | Founding Date 1991 |
Type | Type Private | Type Private | Type Public | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations HQ | Locations Dallas, US HQ | Locations Watertown, US HQ | Locations San Diego, US HQ | Locations Sunnyvale, US HQ |
Employees | Employees 3 | Employees 11 | Employees 77 | Employees 373157% increase | Employees 6551% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 998.7 m | Valuation ($) 6.4 b | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $1.4b (FY, 2025) | Revenue (est.) $729.7m (FY, 2014) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $228.8m (FY, 2025) | Cost of goods $40.4m (FY, 2014) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $1.2b (FY, 2025) | Gross profit $689.3m (FY, 2014) |
Net income | Net income N/A | Net income N/A | Net income ($173m) (FY, 2021) | Net income $316.9m (FY, 2025) | Net income $86.1m (FY, 2014) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 142.5m | Total funding raised $ 171.9m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
ImmuneSensor Therapeutics
HQ
Dallas, US
Employees
11
ImmuneSensor Therapeutics is a company aiming to treat cancer and autoimmune diseases.
View companyFORMA Therapeutics
HQ
Watertown, US
Employees
77
FORMA Therapeutics is a biopharmaceutical company intended for the discovery, development, and commercialization of transformative medicines.
View companyHalozyme Therapeutics
HQ
San Diego, US
Employees
373
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
View companyPharmacyclics
HQ
Sunnyvale, US
Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.
View company